First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM ...Middle East

SHANGHAI, Dec. 17, 2023 /PRNewswire/ -- YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's first in vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis...

Hence then, the article about first patient dosed in clinical trial of yolt 201 for the treatment of hereditary attr cm was published today ( Sunday 17/12/2023 - 06:32 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM )

Also on site :

• Germany plans to take 40% in Leopard tank maker KNDS, joining France as stakeholder
• As public sentiment sours, Indonesia awaits MSCI verdict which risks $13 billion in capital outflows
• Lucid Motors’ new CEO cuts 18% of staff to ‘simplify the company’